期刊文献+

A型肉毒毒素在神经系统疾病中的临床应用 被引量:6

Clinical application of botulinum neurotoxin A in neurological diseases
下载PDF
导出
摘要 A型肉毒毒素(botulinum neurotoxin type A,BoNT/A)是一种嗜神经性的细菌外毒素,具有解痉和镇痛作用,可多次使用,因而在神经系统相关的疾病中得到广泛应用。BoNT/A还参与调节降钙素基因相关肽(calcitonin gene-related peptide,CGRP)、K+和P物质的释放,并具有潜在的抗有丝分裂和抗肿瘤活性,这为扩大BoNT/A应用和研究提供了理论基础。本文就近年A型肉毒毒素在肌张力障碍、痉挛、神经性病理性疼痛、自主神经失调、原发性头痛和脊髓损伤等神经系统相关疾病中的应用以及研究综述,为A型肉毒毒素的运用和研究提供新视角、新指导。 As a kind of neurotropic exotoxin, botulinum neurotoxin type A(Bo NT/A) has a function of muscular paralysis and analgesic. Bo NT/A can be widely used in nervous system-related diseases. It is also involved in regulating the release of calcitonin gene-related peptide(CGRP), K^ and substance P and has potential anti-mitotic and antitumor activity, which will be the basis for the expansion of Bo NT/A application and research. The article reviewed the recent developments in clinical application and research of Bo NT/A in nervous system-related diseases, such as dystonia,spasticity, neuropathic pain, autonomic dysfunction, primary headache and spinal cord injury, which will provide a new perspective and new guidance for application and research of Bo NT/A.
作者 张东亮 赵舒煊 王明 陈铁戈 张海鸿 ZHANG Dongliang;ZHAO Shuxuan;WANG Ming;CHEN Tiege;ZHANG Haihong(Department of Orthopedics,Lanzhou University Second Hospital,Lanzhou 730030;Bone and Joint Disease Research Key Laboratory of Gansu Province,Lanzhou 730030,China)
出处 《临床与病理杂志》 2018年第7期1545-1551,共7页 Journal of Clinical and Pathological Research
基金 甘肃省自然科学基金(17JR5RA238)~~
关键词 肉毒毒素 神经系统 综述 botulinum neurotoxin type A nervous system review
  • 相关文献

参考文献4

二级参考文献30

  • 1韩前河,张雪培,魏金星,王智勇.逼尿肌尿道外括约肌协同失调的肉毒素A治疗[J].临床泌尿外科杂志,2006,21(4):255-256. 被引量:5
  • 2梁志平,杨冬生,李向民.不透X线标志物法对胃排空及胃肠通过时间的测定[J].中国中西医结合影像学杂志,2006,4(3):193-195. 被引量:5
  • 3Schurch B, Stoehrer M, Kramer G, et al. Botulinum -A toxin for treating detrusor hyperreflexia in spinal cord injured patients:a new alternative to anticholinergic drugs? Preliminary results. J Urol, 2000,164:692-697.
  • 4Abrams P,Larsson G, Chapple C, et al. Factors involved in the success of antimuscarintc treatment. BJU Int, 1999,83 (suppl) :42-47.
  • 5Brindley GS. The first 500 patients with sacral anterior root stimulator implants: general description. Paraplegia, 1994,32: 795-805.
  • 6de Seze M, Wiart L, Joseph PA, et al. Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn, 1998,17: 513-523.
  • 7Chancellor MB ,de Groat WC. Intravesical capsaicin and resiniferatoxin therapy:spicing up the ways to treat the overactive bladder. J Urol,1999,162:3-11.
  • 8Madersbacher H, Wyndaele JJ, Igawa Y, et al. Conservative management in the neuropathic patient. In:Abrams P, Khoury S and Wein A,eds. Incontinence. Plymouth: Plymbridge Distributors, 1999. 777-812.
  • 9Brading A. Physiology of bladder smooth muscle. In:Torrens M, Morrison JFB, eds. The physiology of the lower urinary tract. New York:Springer-Verlag, 1987. 161-192.
  • 10Schurch B,Hauri D,Rodic B,et al. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol, 1996,155:1023-1027.

共引文献52

同被引文献46

引证文献6

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部